Fecal Transplantation for Primary Clostridium Difficile Infection

Study Overview
=================
Brief Summary
-----------------
In this randomized controlled trial the investigators want to compare the effect of one-time rectal instillation of fecal microbiota transplantation, compared to a ten-day antibiotic course for the treatment of primary Clostridium difficile infection (CDI). The investigators hypothetsize that the instillation of feces from a healthy donor will be non-inferior to vancomycin in inducing a durable cure.

Detailed Description
-----------------
Up to one third of patients with clostridium difficile infection treated with antibiotics experience recurrent or relapsing symptoms within a few weeks. Even with subsequent antibiotic treatment, multiple recurrences/relapses are frequent. Fecal microbiota transplantation (FMT) has been shown to be significantly more effective in curing recurrent CDI than repeated antibiotic treatment. In current guidelines, FMT is proposed as a treatment option after multiple recurrences/relapses of CDI. The rationale to reserve transplantation of donor feces for recurrent and difficult cases of CDI is a possible risk of pathogen transmittance and the process of finding a donor and screen for communicable disease. The effect of FMT for recurrent CDI, however, suggests that this therapy may be more effective than antibiotics in inducing a durable cure also for primary CDI. If the therapeutic effect of FMT proves to be equal (non-inferior) or more effective than antibiotics, FMT may be the preferable treatment option due to favourable ecological impact compared to antibiotics. In an era with increasing concerns about overuse of antibiotics and emergence of antibiotic resistant bacteria, it is important to investigate therapeutic alternatives that may reduce the need for antibiotics. This trial is a phase III multicentre, randomized controlled, open-label non-inferiority parallel group trial with two arms (FMT and antibiotics), and is a continuation of the phase II trial IMT for Primary Clostridium Difficile Infection (NCT02301000). In the current trial, patients with Clostridium difficile infection and no previous CDI within 12 months prior to inclusion will be randomized 1:1 to FMT or 10 days of guideline-recommended antibiotic therapy (vancomycin 125 mg four times a day). Patients are recruited in Norwegian hospitals. The investigators plan to use frozen microbiota, because supply is easier to organize, compared to fresh fecal samples. Patients in the FMT treatment group will receive one rectal dose of FMT, originating from screened, healthy donors. Patients who are not cured by the first dose is offered a protocol defined additional FMT treatment. In the case of clinical deterioration, appropriate measures will be undertaken according to current guidelines. Patient treatment outcomes are evaluated after 14, 60 and 365 days from inclusion and treatment initiation. An interim analysis is planned after inclusion of the first 94 patients (corresponding to 50% of the planned number of patients).

Official Title
-----------------
COmparative Effectiveness of intestinaL microbiOta Versus vaNcomycin for Primary c. Difficile Infection - randomiZEd Trials

Conditions
-----------------
Clostridium Difficile Infection

Intervention / Treatment
-----------------
* Other: Fecal microbiota transplantation
* Drug: Vancomycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients, ≥18 years with primary C. difficile infection, defined by the following three criteria: Diarrhea as defined by the WHO (≥3 loose stools per day), and Positive stool test for toxin producing C. difficile, and No evidence of previous C. difficile infection during 365 days before enrolment. Written informed consent Exclusion Criteria: Known presence of other stool pathogens known to cause diarrhea. Ongoing antibiotic treatment for other infections that cannot be stopped before study treatment administration. Inflammatory bowel disease or microscopic colitis. < 3 months life expectancy. Serious immunodeficiency, defined as one of the following: Ongoing or recent chemotherapy and current or expected neutropenia with neutrophil count of < 500/μL. Active severe immunocompromising disease. Inability to comply with protocol requirements. Need of intensive care. Known irritable bowel syndrome, diarrheal type. Pregnancy or nursing. Known or suspected toxic megacolon or ileus. Total or subtotal colectomy, ileostomy or colonostomy. Contraindications for rectal catheter insertion Known hypersensitivity or other contraindications to vancomycin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized clinical trial with two parallel treatment arms with a 1:1 allocation.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fecal microbiota transplantation<br>Fecal microbiota from healthy, screened stool donors at the University Hospital of North Norway. Patients will receive one FMT enema immediately after enrolment. | Other: Fecal microbiota transplantation<br>* 50 g donor feces suspended in saline with added glycerol, administered by a enema kit.<br>* Other names: Bacteriotherapy;|
| Active Comparator: Antibiotic treatment<br>Patients randomized to the control group will receive a ten-day course of oral vancomycin four times a day. This is according to international guidelines for primary C. difficile treatment. | Drug: Vancomycin<br>* Peroral vancomycin 125 mg q.i.d. for ten days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients with durable cure | Proportion of patients with primary clinical cure at day 14 after treatment start and no recurrent C. difficile infection during 60 days after treatment start, with the assigned treatment alone. | 60 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients with durable cure with additional treatment. | Proportion of patients with primary clinical cure at day 14 after treatment start and no recurrent C. difficile infection during 60 days after treatment start, with or without the need of additional treatment (FMT, metronidazole or vancomycin). | 60 days | 
| Treatment adverse events | Proportion of patients with adverse events. | 60 and 365 days | 
| Patients with long-time cure | Proportion of patients with primary clinical cure at day 14 after treatment start and no recurrent C. difficile infection during 60 days after treatment start, and without recurrent C. difficile infection within 365 days after treatment start. | 365 days | 
| Health-economic evaluation | Health-economic analysis of the two compared treatment modalities | 365 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Clostridium difficile, Fecal microbiota transplantation, Investigator-initiated, Diarrhea, Intestinal microbiota therapy, Antibiotics